Lung drug safety study in muscle disease patients ends early
NCT ID NCT05335278
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 27 times
Summary
This study looked at whether the drug nintedanib is safe and tolerable for people with a type of lung disease caused by myositis (muscle inflammation). Researchers planned to enroll adults with scarring in the lungs, but the study was stopped early after only 11 participants. The goal was to see how many could stay on the drug for 24 weeks and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Institute McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
Conditions
Explore the condition pages connected to this study.